Brief: Imugene Says FDA Clears IND To Commence Oncarlytics Clinical Study
19/05/2023 02:17
May 19 (Reuters) - Imugene Ltd IMU.AX :
* FDA CLEARS IMUGENE IND TO COMMENCE ONCARLYTICS
FIRST-IN-CLASS
CLINICAL STUDY
Source text for Eikon: ID:nASX5ycB2Y
Further company coverage: IMU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imugene
See all newsAustralia's Imugene rises on fresh responses in blood cancer drug trial
Brief: Imugene Ltd Says Leslie Chong Resigns As CEO
Australia's Imugene loses most in over 8-years on discounted placement
Brief: Imugene To Raise A$11.12 Million Via Placement At A$0.095 Per Share
Brief: Imugene Requests Trading Halt Pending Proposed Capital Raising Announcement